Clinical Trials Browser

Interventional × Rectal Neoplasms × sintilimab × Clear all

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06108596 2025-01-21

PICS

Phase 2 Completed

Gastrointestinal

Rectal Neoplasms

NCT06204094 2025-01-07

CASINOs

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Turcot syndrome, Rectal Neoplasms

NCT05307198 2023-10-10

RAIC

Phase 2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT05450029 2023-09-26

SILAR

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05484024 2022-08-02

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms